CurrentPremera BluecrossPolicy 2.01.533

Upper Gastrointestinal (UGI) Endoscopy in Adults

Customize your policy alerts

Sign up for Premera Bluecross Policy 2.01.533 alerts

Get alerted when Policy 2.01.533 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Medical necessity criteria, site-of-service guidance, documentation, and coding for upper GI endoscopy (EGD) for individuals aged 19 and older; intended for providers and payers reviewing coverage decisions.

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentPremera BluecrossPolicy 2.01.533

Upper Gastrointestinal (UGI) Endoscopy in Adults

Customize your policy alerts

Sign up for Premera Bluecross Policy 2.01.533 alerts

Get alerted when Policy 2.01.533 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerPremera Bluecross

PolicyUpper Gastrointestinal (UGI) Endoscopy in Adults

Policy CodePolicy 2.01.533

Change TypeAnnual review — no material changes

Effective DateSep 1, 2026

Last ReviewJun 16, 2026

Next Review DateSep 1, 2026

Key ActionConfirm documentation of required PPI trial and guideline-based indications when submitting for prior authorization.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

19+applies to individuals aged

8 weeksPPI trial before endoscopy (GERD)

3 monthsminimum GERD/dyspepsia duration

43235-43242sample CPT codes listed

BMI ≥ 50morbid obesity threshold (site-of-service)

Medical Necessity and Coverage Criteria

Medically necessary indications

UGI endoscopy is considered medically necessary when ANY of the following indications are met (malignant indications, alarm symptoms, high‑risk non‑malignant conditions, or other specified indications):

Malignant and high‑risk genetic indications: Barrett esophagus; dysplasia; esophageal cancer; familial adenomatous polyposis (FAP); gastric cancer; head/neck cancer; history of Lynch syndrome or hereditary nonpolyposis; individuals with prior adenomatous or sessile polyps (gastric, duodenal, esophagus); positive CDH1 mutation; family history of gastric, esophageal, or duodenal cancer in a first‑degree relative; tylosis.

Alarm symptoms: Iron deficiency anemia; rectal bleeding or dark/bright blood in stool; epigastric mass on exam; persistent vomiting including hematemesis; dysphagia; unintentional weight loss ≥3 kg since symptoms started.≥ 3 kg weight loss

High‑risk or follow‑up non‑malignant conditions: Evaluation of suspected portal hypertension/cirrhosis to document or treat esophageal varices; follow‑up of eosinophilic esophagitis; follow‑up of erosive esophagitis (may need UGI after a 2‑month course of therapy to evaluate for Barrett); therapeutic banding or sclerotherapy of esophageal varices (repeat until eradication with subsequent surveillance); treatment of bleeding lesions (e.g., ulcers requiring endoscopic therapy); history of gastric surgery; persistent symptoms despite stopping NSAIDs; persistent non‑cardiac chest pain; odynophagia.

Variceal surveillance: 1–3 months post‑eradication then every 6–12 months

GERD/dyspepsia evaluation: Performed for GERD or dyspepsia present ≥3 months AND either persists despite 8 weeks of continuous daily PPI therapy OR is recurrence after PPI discontinuation.3 months; 8 weeks PPI

Other indicated uses: Achalasia; Barrett surveillance per pathology (high‑grade dysplasia: repeat every 3 months for 1 year then annually; low‑grade dysplasia: repeat at 6 months then at 12 months and annually thereafter; no dysplasia: one repeat within 12 months then every 3 years if unchanged); cirrhosis (one screening exam at diagnosis, then no more frequently than annually); Crohn disease involving upper GI; caustic ingestion; foreign body removal; confirmation and follow‑up of gastric/peptic/esophageal ulcers when conservative management failed or is contraindicated (follow‑up every 2 months until healed); pre‑transplant evaluation when UGI pathology would modify management; EUS‑guided FNA/B of adjacent organs/structures; preoperative evaluation prior to bariatric surgery (unless bariatric surgery is contractually excluded); newly diagnosed pernicious anemia within 1 year; post‑cardiac ablation; Barrett screening for males ≥50 years with ≥5 years GERD plus ≥1 risk factor (BMI ≥30, central adiposity, hiatal hernia, night‑time reflux, tobacco use); assessment of diarrhea for small‑bowel disease; evaluation of UGI stricture or obstruction.varies by indication

Not medically necessary

UGI endoscopy is considered not medically necessary in the following scenarios:

Not medically necessary scenarios: Evaluation of chronic, non‑progressive, atypical functional upper GI symptoms (except rare one‑time exam to exclude organic disease when unresponsive to therapy); uncomplicated heartburn that responds to conservative management; procedures where endoscopy results will not alter management; evaluation of asymptomatic or therapy‑responsive radiographic findings (e.g., asymptomatic sliding hiatal hernia, uncomplicated duodenal bulb ulcer that has responded to therapy, deformed duodenal bulb when asymptomatic or responsive to therapy); routine screening of the UGI tract in the absence of a clinical indication; surveillance of healed benign disease (e.g., healed gastric or duodenal ulcer); confirming Helicobacter pylori eradication; surveillance of gastric intestinal metaplasia per this policy text is considered not medically necessary.

Medical necessity criteria (guideline-derived)

Covered when criteria from professional guidelines are met (examples below reflect ACP and ACG recommendations):

Alarm symptoms (ACP): Upper endoscopy is indicated in individuals with heartburn and any of the following alarm symptoms: anemia, bleeding, dysphagia, recurrent vomiting, or weight loss.

Based on ACP Best Practice Advice 1

Refractory GERD or severe disease (ACP): Upper endoscopy is indicated for: (1) typical GERD symptoms that persist despite a therapeutic trial of 4–8 weeks of twice‑daily PPI therapy; OR (2) severe erosive esophagitis after a 2‑month PPI course to assess healing and rule out Barrett esophagus; OR (3) history of esophageal stricture with recurrent dysphagia.

Based on ACP Best Practice Advice 2

High‑risk chronic GERD and surveillance (ACP/ACG): Upper endoscopy may be indicated in men >50 years with chronic GERD (>5 years) plus additional risk factors (nocturnal reflux, hiatal hernia, elevated BMI, tobacco use, central adiposity) to detect esophageal adenocarcinoma and Barrett esophagus; surveillance intervals for Barrett are dysplasia‑stratified (no dysplasia: every 3–5 years; more frequent with dysplasia).

Based on ACP Best Practice Advice 3 and ACG surveillance recommendations

ASGE: General Indications for EGD

Covered when indications align with professional society recommendations (ASGE) and are reasonable and necessary for the individual patient:

ASGE general indications: EGD is generally indicated for evaluating: persistent upper abdominal symptoms despite appropriate therapy; upper abdominal symptoms with signs suggesting serious organic disease or age >45; dysphagia or odynophagia; esophageal reflux persistent or recurrent despite therapy; persistent vomiting of unknown cause; situations where upper GI pathology would modify planned management (e.g., prior ulcer/GI bleeding before transplantation/anticoagulation/long‑term NSAID therapy); familial adenomatous polyposis; confirmation/histologic diagnosis of radiologic lesions or suspected neoplasm; gastrointestinal bleeding (active or recent) or chronic blood loss when an upper source is suspected; when tissue/fluid sampling is indicated; suspected portal hypertension to document/treat varices; assessment after caustic ingestion; treatment of bleeding lesions; banding/sclerotherapy of varices; removal of foreign bodies; removal of selected polypoid lesions; placement of feeding/drainage tubes; dilation of stenotic lesions; management of achalasia; palliative treatment of stenosing neoplasms; endoscopic therapy of intestinal metaplasia; intraoperative evaluation of anatomic reconstructions; management of operative adverse events.

Condensed from ASGE SOP indications.

ASGE: Not Indicated / Surveillance Not Indicated

Not typically covered / not generally indicated when consistent with ASGE guidance:

ASGE: Not indicated: Symptoms considered functional in origin (except possibly a one‑time exam to rule out organic disease if unresponsive to therapy); metastatic adenocarcinoma of unknown primary when results will not alter management; radiographic findings that are asymptomatic or have responded to therapy (asymptomatic or uncomplicated sliding hiatal hernia, uncomplicated duodenal ulcer that responded to therapy, deformed duodenal bulb when asymptomatic or responsive to therapy).

ASGE examples where EGD generally not indicated.

ASGE: Surveillance not indicated: Surveillance EGD generally not indicated for gastric atrophy, pernicious anemia, fundic gland or hyperplastic polyps, gastric intestinal metaplasia, prior benign gastric operations, surveillance of healed benign disease such as esophagitis or gastric/duodenal ulcer, or routine surveillance during repeated dilation of benign strictures unless there is a change in status.

ASGE surveillance recommendations.

ACG 2024: H. pylori test-of-cure

Testing and post‑treatment verification per ACG (H. pylori):

H. pylori test‑of‑cure (ACG 2024): All patients treated for Helicobacter pylori infection should undergo a test‑of‑cure using an appropriately conducted urea breath test, fecal antigen test, or biopsy‑based test at least 4 weeks after completion of therapy. Serology should not be used to confirm eradication.>= 4 weeks post‑therapy

Based on ACG Clinical Guideline: Treatment of H. pylori infection (2024).

Documented policy changes and coverage clarifications (history)

Summary of documented coverage stance changes in history log:

Notable policy decisions recorded: Historical entries document additions and clarifications including: addition of therapeutic banding/sclerotherapy of esophageal varices and specified surveillance intervals; clarification of GERD criteria (PPI trial requirements and duration); addition of UGI for preoperative evaluation prior to bariatric surgery (with contractual exclusions noted); addition of H. pylori and GIM‑related policy statements and test‑of‑cure guidance; addition of post‑cardiac ablation indication and new timing/implementation effective‑date updates.

Refer to history entries for dated details and effective dates.

Routine screening of the upper gastrointestinal (UGI) tract in the absence of a clinical indication is considered not medically necessary. Surveillance endoscopy of healed benign disease (for example, healed gastric or duodenal ulcer) is likewise considered not medically necessary and will not meet coverage unless another covered indication is documented.

Use of a barium swallow for the purpose of diagnosing GERD is not recommended; barium studies should be reserved for evaluation of structural complications such as strictures or rings. Endoscopy is not indicated for GERD symptoms unless conservative management and guideline-recommended trials (for example an empiric PPI trial) have been attempted or alarm features are present.

Esophagogastroduodenoscopy (EGD) is generally not indicated for symptoms considered functional in origin (except in infrequent cases where a one-time exam is performed to exclude organic disease when symptoms are unresponsive to therapy). Other examples where EGD is not indicated include evaluation for metastatic adenocarcinoma of unknown primary when results will not alter management and evaluation of uncomplicated radiographic findings that are asymptomatic or have responded to therapy.

Surveillance of healed benign disease (for example healed gastric or duodenal ulcer or healed esophagitis) is considered not medically necessary. Routine, periodic endoscopic surveillance solely to document prior benign disease healing is not covered unless there is a separate, documented clinical indication that meets medically necessary criteria.

Endoscopy performed primarily for chronic, non‑progressive functional symptoms, or for uncomplicated heartburn that responds to conservative medical management, is considered not medically necessary. Similarly, procedures intended only to obtain findings that will not change clinical management do not meet coverage criteria.

Endoscopy should not be performed for GERD symptoms without first attempting recommended empiric medical therapy. For patients with classic GERD symptoms and no alarm features, an 8‑week trial of once‑daily PPI before a meal is recommended by guideline-based diagnostic approaches; endoscopy is reserved for those who do not respond to an adequate trial or who have alarm features or other indications.

Routine surveillance EGD is generally not indicated for several gastric conditions, including gastric atrophy, pernicious anemia, fundic gland or hyperplastic polyps, gastric intestinal metaplasia, or simply because of prior benign gastric operations. Surveillance solely for these findings without other qualifying indications does not meet medical necessity.

Surveillance of healed benign disease (for example, healed gastric or duodenal ulcers) is reiterated as not medically necessary. The policy history and statements consistently clarify that follow-up endoscopy solely to document healed benign lesions is not a covered indication unless specific medically necessary criteria are present.

Billing and Coding

Covered CPT CodesCPTCovered

43235	Esophagogastroduodenoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure).
43238	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s), (includes endoscopic ultrasound examination limited to the esophagus, stomach or duodenum, and adjacent structures).
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple.
43242	Esophagogastroduodenoscopy, flexible, transoral; with transendoscopic ultrasound-guided intramural or transmural fine needle aspiration/biopsy(s) (includes endoscopic ultrasound examination of the esophagus, stomach, and either the duodenum or a surgically altered stomach where the jejunum is examined distal to the anastomosis).

Historical CPT codes noted in policy historyCPT

43233	CPT code referenced as added in 2014 (informational removal noted in history)
43234	CPT code referenced as removed from informational list in history
43237	CPT code referenced as removed from informational list in history
43240	CPT code referenced as removed from informational list in history
43241	CPT code referenced as removed from informational list in history

Historical CPT code additions/removals referencedCPT

43233	informational CPT code listed in historical removals
43234	informational CPT code listed in historical removals
43237	informational CPT code listed in historical removals
43240	informational CPT code listed in historical removals
43241	informational CPT code listed in historical removals
43243	informational CPT code listed in historical removals
43244	informational CPT code listed in historical removals
43245	informational CPT code listed in historical removals
43246	informational CPT code listed in historical removals
43247	informational CPT code listed in historical removals

1–10 of 22

1/3

BMI threshold for morbid obesity used in site-of-service considerations

BMI thresholdMorbid obesity defined as BMI ≥ 50 kg/m² (site-of-service consideration)

ContextUsed in site-of-service review for elective diagnostic or surgical procedures to identify increased risk for complications

ImplicationPatients with BMI ≥ 50 may require higher-acuity site (e.g., inpatient) or specific justification for ASC/outpatient setting

Documentation, Authorization, and Provider Responsibilities

Prior Authorization

Site-of-service review required for elective diagnostic endoscopy

Review site-of-service medical necessity for elective diagnostic endoscopy and document reasons if performing outside an ambulatory surgical center (ASC); ASC or outpatient settings are preferred unless one of the policy exceptions applies (no ASC access within 30 miles, no physician privileges at ASC, ASC guideline prohibits use, patient age ≤18, additional service requires hospital outpatient setting, or increased clinical risk factors such as ASA III+, recent MI/stroke, advanced liver disease, severe pulmonary or cardiac risk, morbid obesity BMI ≥50, pregnancy, or other listed risks).

Preferred medically necessary sites: ASC; off-campus or on-campus outpatient hospital/medical center.
Exceptions permitting hospital outpatient: no ASC access within 30 miles, lack of physician privileges, ASC guideline/weight restrictions, age ≤18, or concurrent additional service requiring hospital outpatient.
Document clinical risk factors (ASA classification, recent MI/CVA, advanced liver disease/MELD >8, COPD/FEV1 thresholds, morbid obesity BMI ≥50, etc.) if site requires hospital setting.

Prior Authorization

Authorization must confirm PPI trial and guideline-based indications

Background and Scope

Upper gastrointestinal endoscopy (EGD/UGI) inspects the esophagus, stomach, and proximal duodenum using a flexible endoscope inserted via the mouth, commonly under sedation. It is used for diagnostic evaluation (for example biopsy, tissue sampling) and for therapeutic interventions such as polypectomy, dilation, variceal banding, foreign body removal, and endoscopic hemostasis when clinically indicated.

Definitions

Achalasia — definition

TermAchalasia

DefinitionAn esophageal motility disorder involving the smooth muscle of the esophagus and the lower esophageal sphincter (LES).

RelevanceListed as an indication for EGD (management and therapeutic interventions such as dilation or botulinum toxin).

Barrett esophagus — definition (metaplastic columnar/glandular epithelium replacing squamous epithelium)

TermBarrett esophagus

DefinitionReplacement of normal squamous esophageal epithelium by metaplastic columnar or glandular epithelium (often due to GERD), which predisposes to esophageal adenocarcinoma.

Policy History and References

Documented policy changes and coverage clarifications (history)

History (timeline of notable edits and coverage clarifications):

06/02/15 – 01/01/19 entries: Policy updates and related policy removals; added clarifications including positive CDH1 mutation and modified alarm symptom descriptions.

Chunks 57

2018–2020 entries: 2018 reorganized criteria and added surveillance for cirrhosis; 2020 policy deletion and reinstatement noted (effective dates recorded).

Chunks 57–58

2021–2024 entries: Clarified follow‑up after erosive esophagitis (two‑month therapy), modified GERD criteria to require 8 weeks continuous daily PPI or recurrence after stopping PPI, added therapeutic banding of varices, added EUS‑guided FNA indication, and adjusted Barrett surveillance intervals including low‑grade dysplasia timing in 2024.

Chunks 59–60

Policy Summary

PayerPremera Bluecross

PolicyUpper Gastrointestinal (UGI) Endoscopy in Adults

Policy CodePolicy 2.01.533

Change TypeAnnual review — no material changes

Effective DateSep 1, 2026

Last ReviewJun 16, 2026

Next Review DateSep 1, 2026

Key ActionConfirm documentation of required PPI trial and guideline-based indications when submitting for prior authorization.

SourceLink

On This Page

Diagnostic approach per ACG: For patients with classic GERD symptoms and no alarm signs, an 8‑week trial of empiric once‑daily PPI is recommended before endoscopy; diagnostic endoscopy is recommended for patients not responding to an 8‑week empiric PPI trial or whose symptoms return when PPIs are discontinued; endoscopy is first‑line for dysphagia or alarm symptoms and for patients with multiple Barrett risk factors.8 weeks PPI

Based on ACG recommendations

When submitting for authorization, confirm guideline-based indications and that empiric acid-suppression therapy was trialed as appropriate (e.g., an 8-week once-daily PPI trial for classic GERD or 4–8 weeks twice-daily PPI per ACP/ACG when indicated), or document reasons an empiric PPI trial was not appropriate.

Authorization should note presence/absence of alarm symptoms or other guideline-based risk factors.
If GERD/dyspepsia indication, document PPI trial duration and response or reason for exception.

Prior Authorization

Prior authorization: document reasonable & necessary indication

Obtain prior authorization per Premera rules where required and ensure the requested endoscopic procedure is reasonable and necessary for the individual patient; lack of medical necessity per criteria may result in denial.

Prior authorization decisions follow payer rules and Medicare national coverage concept of "reasonable and necessary."
Provide documentation that the procedure addresses a covered indication and will alter management when applicable.

Prior Authorization

Verify benefits and prior authorization requirements with Premera

Verify member benefits and any prior-authorization requirements with Premera before scheduling; this policy does not list prior authorization codes and coverage is subject to member contract limits.

Consult the member benefit booklet or contact member services to determine plan-specific coverage and limits.
Confirm whether prior authorization is required for the planned CPT code and site of service.

Step Therapy

PPI trial — document 8 weeks continuous daily therapy when indicated

For GERD or dyspepsia, document an expected trial of 8 weeks of continuous daily PPI therapy prior to routine diagnostic endoscopy unless symptoms recurred after stopping PPI or another guideline-consistent exception applies.

Record PPI name, dose, start and end dates, and response.
If PPI intolerant or contraindicated, document reason and alternative therapy used.

Step Therapy

Document trial of appropriate medical therapy (PPI; H2RA if intolerant)

Document a trial of appropriate acid-suppressive therapy (PPI; H2RA only if PPI intolerant) at guideline doses before routine EGD for GERD without alarm features; include medication, dose, duration, and clinical response.

Use Table 1 dosing as documented for PPI or H2RA when substituting.
Record lack of response to therapy if proceeding to endoscopy.

Step Therapy

When guidelines require therapy trial prior to EGD, document trial and response

Where professional guidelines recommend a trial of therapy prior to EGD (for example, empiric PPI trial for classic GERD), document that the trial occurred and the patient's response before routine endoscopy is performed.

Indicate whether the trial was therapeutic (adequate dose and duration) and whether symptoms persisted or recurred.
If proceeding without recommended trial, document clinical justification (alarm features, dysphagia, weight loss, etc.).

Documentation Required

Required clinical documentation: malignant indications, alarm features, high-risk conditions, and PPI trial details

Include in clinical notes the malignant indications, alarm symptoms, high-risk non-malignant conditions requiring follow-up or treatment, and GERD/indigestion duration and PPI trial details (8 weeks continuous daily PPI or recurrence after discontinuation) when applicable.

Document malignant indications or alarm symptoms explicitly (anemia, bleeding, dysphagia, recurrent vomiting, weight loss).
For high-risk non-malignant conditions list (portal hypertension/cirrhosis, eosinophilic esophagitis, erosive esophagitis, varices, prior gastric surgery, odynophagia, etc.).
Record GERD duration (≥3 months) and PPI trial details (dose, duration, response).

Documentation Required

Document alarm symptoms, PPI trial dose/duration/response, and prior cardiac evaluation for chest pain

Document alarm symptoms, the duration and response to therapeutic PPI trials (including specific dose and duration), and prior cardiac evaluation when chest pain is present to show non-cardiac etiology before endoscopy.

Record specific alarm features: anemia, bleeding, dysphagia, recurrent vomiting, weight loss.
Include prior cardiac evaluation results when evaluating non-cardiac chest pain.

Documentation Required

Document indication and prior therapy consistent with guideline-based requirements

Ensure the indication submitted for authorization and documented in the chart aligns with guideline-based indications (e.g., persistent symptoms despite appropriate therapy, alarm features, need for tissue sampling or therapeutic intervention) and include prior conservative therapy when relevant.

State the clinical indication and which guideline-based criterion it meets.
Attach or summarize prior conservative management steps (medications, lifestyle, H2RA trial if PPI intolerant).

Billing Rule

Verify member benefits and plan-specific limitations prior to scheduling

Verify member-specific coverage and any benefit limitations before scheduling; consult the member benefit booklet or contact customer service because member contracts differ and benefits may limit coverage.

Confirm whether the planned procedure and site of service are covered under the member's plan.
Document verification steps (date, representative contacted, and findings) in the chart or authorization request.

Denial Risk

Denial trigger — endoscopy not medically necessary when criteria not met

Be aware that UGI endoscopy will be denied as not medically necessary when the documented clinical criteria are not met — including for chronic, non-progressive functional symptoms, uncomplicated heartburn responsive to conservative therapy, procedures that will not alter management, routine screening without indication, or surveillance of healed benign disease.

If symptoms are functional and non-progressive, document why endoscopy is justified or expect potential denial.
Surveillance of healed benign disease and routine screening without indication are considered not medically necessary per policy.

Denial Risk

Denial risk when EGD performed before conservative management or cardiac causes excluded

Do not perform routine EGD before attempting conservative management (e.g., empiric PPI trial) or before excluding cardiac causes of chest pain; performing EGD without these steps when indicated increases risk of denial.

Document attempts at conservative management and any cardiac workup results to support medical necessity.
If proceeding without conservative therapy due to alarm features, explicitly document those features.

Denial Risk

Reasonable and necessary coverage trigger — confirm individual medical necessity

Confirm that the procedure is reasonable and necessary for the individual patient per Medicare/National Coverage standards; procedures judged not reasonable and necessary may be denied.

Provide documentation supporting how the procedure is expected to change management or address an indication covered by the policy.
Cite relevant guideline-based indications in the authorization or medical record when helpful.

Billing Rule

Verify benefit limitations and document verification

Coverage is subject to the member's benefit plan limits and conditions; verify plan coverage, applicable limitations, and document verification because member contracts differ and may restrict coverage.

Check for site-of-service, prior authorization, and frequency/coverage limits in the member's benefit booklet.
Document the benefit verification interaction (date, contact, and result).

Barrett esophagus is a premalignant condition prompting surveillance EGD per dysplasia-stratified intervals.

Crohn disease — definition

TermCrohn disease

DefinitionA type of inflammatory bowel disease (IBD) that may affect any part of the gastrointestinal tract from mouth to anus.

RelevanceUGI endoscopy may be indicated when Crohn disease involves the upper GI tract.

Celiac disease — definition

TermCeliac disease

DefinitionAn autoimmune digestive disorder (gluten-sensitive enteropathy) in which ingestion of gluten damages the intestinal lining.

Clinical noteSerology tests are used in diagnosis; UGI may assess small-bowel disease when clinically indicated.

Cirrhosis — definition and relation to varices

TermCirrhosis

DefinitionScarring of the liver due to injury or long-term disease; common causes include chronic alcoholism and hepatitis.

Relation to varicesCirrhosis can be associated with portal hypertension and esophageal varices; EGD may be used to document or treat varices (e.g., banding/sclerotherapy).

Dyspepsia — definition

TermDyspepsia

DefinitionChronic or recurrent pain or discomfort centered in the upper abdomen; may include frequent heartburn or acid regurgitation.

Clinical useUGI endoscopy is used to investigate causes of severe dyspepsia when indicated by duration or failure of therapy.

Dysphagia — definition

TermDysphagia

DefinitionDifficulty or inability to swallow.

Clinical noteDysphagia is an alarm symptom frequently prompting endoscopic evaluation (EGD).

Esophagogastroduodenoscopy (EGD) — definition (upper gastrointestinal endoscopy)

TermEsophagogastroduodenoscopy (EGD)

DefinitionA flexible endoscopic examination of the upper gastrointestinal tract (esophagus, stomach, and proximal duodenum) performed for diagnosis and some therapies, usually under light sedation.

Also known asUGI endoscopy or gastroscopy; used to inspect, biopsy, surveil, and perform therapeutic interventions.

Barrett esophagus (duplicate inventory entry) — definition

TermBarrett esophagus

DefinitionMetaplastic columnar or glandular epithelium replacing normal squamous epithelium of the esophagus, often related to GERD and increasing adenocarcinoma risk.

SurveillanceSurveillance intervals are stratified by dysplasia status per policy guidance.

Achalasia (duplicate inventory entry) — definition

TermAchalasia

DefinitionAn esophageal motility disorder involving the smooth muscle of the esophagus and the lower esophageal sphincter (LES).

ManagementEGD has roles in management such as dilation or botulinum toxin for achalasia-related obstruction.

Medical management — definition (non-invasive interventions such as medications, counseling)

TermMedical management

DefinitionNon-invasive interventions such as acid-suppressive medications, nutritional counseling, weight loss counseling, and environmental changes (e.g., elevating the head of bed).

RoleExpected prior to endoscopy for many GERD/dyspepsia presentations (documented PPI trials per policy).

Esophagogastroduodenoscopy (EGD) — alternate definition entry

TermEsophagogastroduodenoscopy (EGD)

Alternate definitionA flexible tubelike instrument inserted through the mouth permitting visual inspection of the esophagus, stomach, and first part of the small intestine (upper duodenum); diagnostic and therapeutic uses.

Typical sedationUsually performed under light IV sedation.

GERD — definition and guideline context

TermGERD (Gastroesophageal reflux disease)

DefinitionA chronic disorder of the lower esophageal sphincter where stomach contents reflux into the esophagus causing heartburn, regurgitation, and sometimes noncardiac chest pain.

Guideline contextACG recommends an 8‑week trial of once-daily PPI for classic GERD symptoms before endoscopy; diagnostic endoscopy for those not responding or with alarm features.

Esophagogastroduodenoscopy (EGD) — ASGE-context definition

TermEsophagogastroduodenoscopy (EGD)

ASGE-context definitionEndoscopic evaluation of the upper gastrointestinal tract used for diagnosis, biopsy, surveillance, and therapeutic interventions per ASGE indications and standards of practice.

IndicationsASGE lists persistent upper abdominal symptoms, dysphagia, GI bleeding, suspected portal hypertension/varices, and many therapeutic uses among indications for EGD.

UGI — definition (upper gastrointestinal endoscopy, used interchangeably with EGD in prior versions)

TermUGI (Upper gastrointestinal endoscopy)

DefinitionUpper gastrointestinal endoscopy (used interchangeably with EGD) — diagnostic and therapeutic endoscopic evaluation of the esophagus, stomach, and duodenum using a flexible endoscope.

UsageTerm has been used interchangeably with EGD in prior versions of the policy.

2025–2026 entries: Policy language refined around H. pylori eradication confirmation (not covered), added site‑of‑service ASC guidance, and updated effective dates (multiple postponements to Sept 1, 2026 in history log).

2013-06-10policy_created

New policy created and added to UGI endoscopy coverage (initial publication).

2015-06-02related_policies_updated

Updated related policies; removed policy 2.01.81 and later removed 6.01.33 and 7.02.500 in 2015 updates.

2016-02-09annual_review

Annual review completed; no change to coverage statements and removal of a Medicare LCD reference.

2017-01-01interim_review

Clarified bleeding descriptions in Alarm Symptoms and changed 'gastric bypass surgery' to 'bariatric surgery' in Other UGI Indications; replaced acronym 'EGD' with 'UGI' for consistency in a minor 2017 update.

2018-01-01annual_review

Modified criteria to include surveillance for individuals with cirrhosis, clarified bariatric surgery exclusion language, reorganized policy criteria, and added documentation requirements.

2018-09-01interim_review

Added surveillance criteria for Barrett's esophagus without dysplasia and re-added age consideration previously removed.

2019-01-01interim_review

Added positive CDH1 mutation as an indication.

2019-06-01annual_review

Added medically necessary statement post cardiac ablation for arrhythmia treatment and updated references.

2019-12-01effective_date_change

Policy effective date was updated to January 1, 2020.

2020-04-01deletion_intended

Policy scheduled for deletion effective July 2, 2020 and replacement by policy 10.01.530 (subsequently deleted on 07/02/20).

2020-11-01policy_reinstated

Policy reinstated effective February 5, 2021 following review; references added and policy reviewed.

2021-06-01criteria_clarification

Clarified follow-up therapy to include a two-month course for known erosive esophagitis and performed annual review with references updated.

2022-06-01policy_modification

Modified GERD/dyspepsia criteria to require persistence despite 8 weeks of continuous daily PPI therapy or recurrence after PPI discontinuation; added eosinophilic esophagitis follow-up; removed H2 blocker statement; effective for services on or after 2022-09-02.

2022-09-01interim_review

Added therapeutic banding or sclerotherapy of esophageal varices as medically necessary, clarified variceal surveillance, and changed preoperative UGI prior to bariatric surgery to medically necessary.

2023-02-01interim_review

Added follow-up UGI for gastric, peptic, or esophageal ulcer every 2 months until healed and stated surveillance of healed benign disease is not medically necessary; other clarifications and standardization of terminology.

2023-10-01annual_review

Added statement that UGI is medically necessary for endoscopic ultrasound-guided fine needle aspiration/biopsy(s) of adjacent organs or structures; references updated.

2024-03-01interim_review

Updated Barrett's esophagus surveillance criteria to specify low-grade dysplasia repeat interval (6 months then 12 months and annually) and removed other dysplasia grade criteria.

2024-05-01annual_review

Clarified family history indication for first-degree relatives with gastric, esophageal, or duodenal cancer and updated references.

2025-08-12annual_review

Annual review completed; added statements that UGI is not medically necessary for confirming H. pylori eradication and other minor clarifications.

2026-02-24effective_date_change

Policy effective date updated from March 4, 2026 to May 1, 2026 due to operational readiness.

2026-03-27effective_date_change

Policy effective date updated from May 1, 2026 to July 1, 2026 due to operational readiness.

2026-06-01minor_update

Added header clarifying that site-of-service review does not apply to Indian Health Services (IHS) facilities.

2026-06-16effective_date_changeLatest

Policy effective date updated from July 1, 2026 to September 1, 2026 due to operational readiness (current effective date).

This policy references multiple professional society guidelines and other sources, including ASGE standards of practice, ACG diagnostic and surveillance recommendations (including the ACG guidance on empiric PPI trials), ACP Best Practice Advice, and Medicare national coverage guidance. The document history and references list these guideline sources and other supporting literature used to define medically necessary and not medically necessary scenarios.